



Subject: Reference pricing on proton pump inhibitors (PPIs)

As outlined in the communication sent to you by the OSSTF ELHT in June, changes are being made to coverage for PPIs under the OSSTF ELHT Benefits Plans.

For eligible members and their dependants who are enrolled in the OSSTF ELHT Extended Health Care benefit, starting on September 1, 2026, the plan will apply a maximum allowable cost for PPIs. This limit is based on the cost (reference pricing) of generic pantoprazole, which is in the same drug category.

This means that if your prescribed PPI costs more than the plan's maximum allowable cost, you will need to pay the difference. You may want to speak with your doctor or pharmacist about your medication options.

This change applies to both brand-name and generic PPIs, such as esomeprazole, omeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole.

An appeal process is available, which may allow coverage above the maximum allowable cost if supporting medical documentation demonstrates that an alternative treatment is medically necessary.

Click the link to open the **Reference-based Pricing (RBP) Exception Request Form**: [Proton-Pump-Inhibitor-\(PPI\)-Appeal-Form.pdf](#). The form is also available at otipraeo.com/forms in the **Group Benefits** drop-down menu.

Have questions? Log in to My Member Account at member.otip.com to contact us, access live chat or visit our Help centre to find answers to your questions.